Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with substance use disorder (SUD) and is associated with poor substance-use treatment outcomes. A trial evaluating osmotic-release oral system methylphenidate (OROS-MPH) for adolescents with ADHD and SUD, concurrently receiving behavioral therapy, revealed inconsistent medication effects on ADHD or SUD. Clinical care for this population would be advanced by knowledge of treatment outcome predictors. Data from the randomized placebo-controlled trial (n = 299) were analyzed. Significant treatment predictors included: 1) Substance use severity, associated with poorer ADHD and SUD outcomes, 2) ADHD severity, associated with better ADHD and SUD outcomes, 3) comorbid conduct disorder, associated with poorer ADHD outcomes, and 4) court-mandated status, associated with better SUD outcomes but poorer treatment completion. An interaction effect showed that OROS-MPH improved SUD outcomes in adolescents with comorbid conduct disorder compared to placebo. While severe SUD may require more intensive psychosocial treatment, OROS-MPH may improve substance treatment outcomes in adolescents with co-morbid attention and conduct problems.
Original language | English (US) |
---|---|
Pages (from-to) | 224-230 |
Number of pages | 7 |
Journal | Journal of Substance Abuse Treatment |
Volume | 44 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2013 |
Keywords
- Attention-Deficit/Hyperactivity Disorder
- Conduct disorder
- OROS-MPH
- Predictors of treatment response
- Substance Use Disorder
ASJC Scopus subject areas
- Phychiatric Mental Health
- Medicine (miscellaneous)
- Clinical Psychology
- Psychiatry and Mental health